Chemours Co
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
CC$13.48+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net (loss) income | $(4) | $54 |
| Adjustments to reconcile net income to cash used for operating activities: | ||
| Depreciation and amortization | 88 | 71 |
| Gain on sales of assets and businesses | (1) | (3) |
| Equity in earnings of affiliates, net | (7) | (11) |
| Amortization of debt issuance costs and issue discounts | 3 | 3 |
| Deferred tax (benefit) provision | (15) | — |
| Asset-related charges | 1 | — |
| Stock-based compensation expense | 5 | 1 |
| Net periodic pension cost | — | 1 |
| Defined benefit plan contributions | (4) | (4) |
| Other operating charges and credits, net | 37 | (11) |
| Decrease (increase) in operating assets: | ||
| Accounts and notes receivable, net | (111) | (186) |
| Inventories and other current operating assets | (51) | (29) |
| Other non-current operating assets | 48 | 31 |
| (Decrease) increase in operating liabilities: | ||
| Accounts payable | (105) | (156) |
| Other current operating liabilities | (5) | (46) |
| Other non-current operating liabilities | 9 | (5) |
| Cash used for operating activities | (112) | (290) |
| Cash flows from investing activities | ||
| Purchases of property, plant, and equipment | (84) | (102) |
| Proceeds from sales of assets and businesses | — | 3 |
| Foreign exchange contract settlements, net | (2) | (2) |
| Cash used for investing activities | (86) | (101) |
| Cash flows from financing activities | ||
| Debt repayments | (8) | (3) |
| Payments on finance leases | (3) | (3) |
| Proceeds from supplier financing program | 27 | 27 |
| Payments to supplier financing program | (35) | (37) |
| Proceeds from exercised stock options, net | — | 1 |
| Payments related to tax withholdings on vested stock awards | (1) | (2) |
| Payments of dividends to the Company's common shareholders | (37) | (37) |
| Cash used for financing activities | (57) | (54) |
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents | 6 | (9) |
| Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents | (249) | (454) |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1, | 763 | 1,807 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at March 31, | $514 | $1,353 |
| Supplemental cash flows information | ||
| Non-cash investing and financing activities: | ||
| Purchases of property, plant, and equipment included in accounts payable | $26 | $44 |
Note 1. Background, Description of the Business, and Basis of Pre
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.